Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

28°
- Benton, AR (72018)
  Today
  
  Plentiful sunshine. High 42F. Winds SSW at 5 to 10 mph..
  
  Tonight
  
  Clear skies. Low 28F. Winds light and variable.
  
  Updated: December 15, 2025 @ 10:10 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

6.035 -0.315 (-4.96%)

Streaming Delayed Price Updated: 11:37 AM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

November 17, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 13, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

November 04, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 03, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

October 16, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

October 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

October 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

October 03, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 29, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 17, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

September 02, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

August 28, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

July 24, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

July 09, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

June 24, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

June 23, 2025

Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 06, 2025

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 28, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 27, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 22, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at Upcoming Investor Conferences

May 06, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

April 23, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

April 01, 2025

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

March 26, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

March 20, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

March 18, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 13, 2025

From Candel Therapeutics

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

Press Releases about Candel Therapeutics, Inc. - Common Stock

Sections

Services

Follow Us